Helen Chen, M.D.
Associate Chief and Senior Investigator, Cancer Therapy Evaluation Program
National Cancer Institute
Dr. Chen has been responsible for strategic planning and oversight of the National Cancer Institute’s (NCI) clinical development programs for signal transduction agents including HER2/EGFR, IGF-1R and RAF/MEK targeting agents, anti-angiogenesis therapies and antibody-based therapeutics. She is also involved in NCI’s initiatives in biomarkers and novel combination strategies and serves on the NCI experimental therapeutics committee, angiogenesis task force and the Clinical Assay Development Program.
Dr. Chen is on the organizing committee of the International Symposium of Anti-angiogenesis Therapy, the scientific committees for the EORTC-AACR-NCI Annual Meeting on Molecular Targeted Therapy, the ASCO-NCI-EORTC Annual Biomarkers Symposium, and the Biotherapy Development Association. She has been an invited speaker at national and international meetings on cancer drug development strategies, and is the first or coauthor of more than 30 original and review papers in peer-reviewed journals including the Journal of Clinical Oncology, Nature Reviews, and the New England Journal of Medicine.